Regulatory Momentum for Daraxonrasib and RAS Pipeline Upside Support Charles Zhu’s Buy Rating on RVMD with Unchanged $263 Price Target
I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Charles Zhu maintained a Buy rating on Revolution Medicines (RVMD) with an unchanged $263 price target, citing regulatory momentum for daraxonrasib in pancreatic cancer following FDA NDA acceptance. The thesis highlights robust Phase 3 data, potential Q3 launch, and commercial upside from converting existing patients. J.P. Morgan also maintained a Buy rating with a $205 target.
Analyst Charles Zhu of LifeSci Capital maintained a Buy rating on Revolution Medicines, retaining the price target of $263.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Charles Zhu has given his Buy rating due to a combination of factors, foremost among them the regulatory momentum behind daraxonrasib in pancreatic cancer. The FDA’s acceptance of the NDA for previously treated metastatic PDAC, backed by robust Phase 3 RASolute 302 data, positions the drug as a potential new standard of care, with the EMA also moving quickly on review.
Zhu also sees near-term commercial upside, noting that a 3Q launch is increasingly plausible and could be accompanied by a meaningful revenue boost from converting existing EAP patients to commercial use. While some investors are focused on the speculative possibility of a line-agnostic, first-line accelerated approval, his thesis rests more on the high probability of approval in the post-1L setting and the broader RAS inhibitor pipeline, all supporting the unchanged $263 price target and a favorable risk-reward profile for RVMD.
In another report released yesterday, J.P. Morgan also maintained a Buy rating on the stock with a $205.00 price target.